Login to Your Account

Regenxbio hunts rare genetic disorders with new academic deals

By Michael Fitzhugh
Staff Writer

Wednesday, April 8, 2015

Gene therapy developer Regenxbio Inc. has shored up key IP rights and relationships supporting its preclinical therapies for the rare genetic diseases Hurler and Hunter syndromes, executing two exclusive new license and research agreements with the universities of Pennsylvania and Minnesota. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription